Descripción de la empresa
REGENXBIO Inc. operates as a clinical-stage biotechnology entity dedicated to the development and commercialization of gene therapies designed to deliver functional genes into cells harboring genetic defects within the United States market. The company's proprietary product candidates are fundamentally built upon the NAV Technology Platform, which utilizes a specialized adeno-associated virus vector system for gene delivery. This firm functions within the broader Healthcare sector, specifically targeting the high-growth and high-risk Biotechnology industry where innovation in genetic medicine defines competitive advantage. With a market capitalization of $400.52M and a workforce of 371 employees, the organization maintains a mid-cap profile typical of pre-revenue or clinical-stage entities that have not yet achieved consistent profitability. The combination of a market cap under half a billion dollars and a trailing twelve-month revenue of $170.44M indicates that the company is currently in a phase of scaling operations and generating sales, yet it remains dependent on future commercial milestones to transition into a sustained cash-flow positive status.
Salud financiera
The company reported revenue of $170.44M over the trailing twelve months, while posting a net income of $-193,878,000 and an EBITDA of $-145,583,008. The substantial disparity between the positive revenue figure of $170.44M and the deeply negative net income reveals a cost structure characterized by significant operating expenses, likely driven by research and development costs, manufacturing overhead, and commercialization expenditures inherent to clinical-stage biotechnology. Free cash flow stood at $-79,794,752, indicating that the company is currently consuming cash reserves to fund its operations and growth initiatives rather than generating surplus liquidity for distribution or debt repayment. Gross margin was recorded at -45.9%, operating margin at -190.0%, and profit margin at -113.8%, figures that collectively demonstrate the company is not yet covering its direct costs of goods sold or overall operating expenses with its current revenue stream, a common characteristic for firms in the early commercialization phases. The balance sheet shows cash holdings of $230.07M against total debt obligations of $260.52M, resulting in a debt-to-equity ratio of 253.59, which suggests the company is currently in a leveraged position where liabilities significantly exceed equity. Despite the high leverage, the current ratio of 2.38 indicates a conservative stance on short-term liquidity, as current assets are more than twice the value of current liabilities, providing a buffer against immediate financial obligations. Return on Equity is -107.0% and Return on Assets is -21.9%, metrics that explicitly reveal that management is currently allocating capital in a manner that results in value destruction on an accounting basis, reflecting the heavy investment required to advance clinical trials and product development before the business model can become accretive.
Evaluación de valoración
The valuation metrics for REGENXBIO present a complex picture due to the lack of profitability, evidenced by a trailing P/E ratio of N/A and a forward P/E of -3.53. The absence of a trailing P/E ratio implies that earnings per share are negative, making traditional multiple-based valuation methods inapplicable, while the negative forward P/E suggests the market expects earnings to remain negative or for the company to continue burning cash in the near term. The price-to-book ratio stands at 3.84, indicating that the market is pricing the company at a significant premium relative to its net asset value, a phenomenon often seen in biotechnology firms where intellectual property and clinical pipeline potential outweigh the value of tangible assets. Alternative valuation metrics such as the price-to-sales ratio of 2.35 and an EV/EBITDA of -2.96 provide context for investors assessing the company based on revenue generation and enterprise value relative to earnings before interest, taxes, depreciation, and amortization, though the negative EV/EBITDA confirms the entity is not yet profitable. The stock has traded within a 52-week range between a high of $16.19 and a low of $5.04, with the current share price situated below the recent highs, reflecting the market's cautious sentiment regarding the company's path to profitability. The beta value of 1.14 signifies that the stock exhibits higher volatility than the broader market, meaning price fluctuations will likely be amplified relative to general market movements, which is typical for smaller biotechnology companies with limited liquidity.
Growth & Income
Revenue growth for the trailing twelve months reached 43.0% year-over-year, while earnings growth is listed as N/A due to the company's continued losses. The divergence between robust revenue expansion and the absence of earnings growth highlights a stage where top-line scaling is occurring faster than bottom-line profitability, implying that revenue gains are currently being absorbed by rising costs associated with scaling production and commercial efforts. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that it does not distribute profits to shareholders but instead retains all earnings to fund research, development, and operational expansion. This reinvestment strategy is standard for clinical-stage biotechnology firms that prioritize funding their clinical trials and platform technologies over shareholder returns. The overall growth and income profile is characterized by strong revenue acceleration and zero dividend distribution, positioning the company as a pure growth play reliant on future product approvals and market uptake to eventually generate positive cash flows and potentially alter its capital allocation strategy.